Vertex Pharmaceuticals Stock News

Alphabet should continue to benefit from a strong AI tailwind in 2026. Vertex Pharmaceuticals has several growth drivers in the new year.

Vertex Pharmaceuticals remains a 'Top Idea' with robust Q3 earnings, a dominant CF franchise, and a broadening late-stage pipeline. VRTX's diversification into pain, kidney, cell, and gene therapies positions it for multiple launches between 2026–2028, supporting long-term growth. Financial strength is evident with $12B in cash, upgraded 2025 revenue guidance ($11.9B–$12B), and accelerating com...

Vertex could have several catalysts in 2026, helping it set a strong foundation for the future. DexCom is expanding its addressable market in order to help deal with some current challenges.

Amazon's profitability underscores the success of established and emerging growth sources. Vertex Pharmaceuticals is launching several new products, and more approvals could be around the corner.

Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it's been on the rise. This other biotech has proven itself as a long-term winner.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Inves...

December's mixed performance for tech may be an early signal that leadership is narrowing, especially among the value-stretched stocks. Investors looking forward to 2026 may find better risk-adjusted opportunities in defensive sectors with select growth drivers. Rather than relying solely on traditional names, this article digs deeper into Quant Strong Buys that combine durable cash flows, esse...

Microsoft shares underperformed due to concerns about its relationship with OpenAI following the Oracle/OpenAI deal announcement. Vertex Pharmaceuticals lost value following disappointing clinical trial results in one of its pain therapy programs. We initiated a position in Advanced Micro Devices (AMD), a leading provider of high-performance computing and AI solutions.